Also trades as: 0M3Q.L (LSE) · $vol 1M · ZOE.DE (XETRA) · $vol 0M

$81.32

+1.25 (+1.56%)

Weekly Expected Move ±11.3%

$58 $66 $74 $83 $91

NYSE · Healthcare · Drug Manufacturers - General · Alpha Radar Sell · Power 42 · $34.1B mcap · 418M float · 1.29% daily turnover · Short 33% of daily vol

Revenue Segmentation

By Product / Service

By Geography

Revenue by Segment (5-Year Trend)

Income Trends

Revenue

$9.5B +2.3% ▲

5Y CAGR: +7.2%

Gross Profit

$6.7B +4.3% ▲

5Y CAGR: +8.4%

Operating Income

$3.6B +6.0% ▲

5Y CAGR: +9.7%

Net Income

$2.7B +7.5% ▲

5Y CAGR: +10.3%

EPS (Diluted)

$6.02 +10.1% ▲

5Y CAGR: +12.0%

EBITDA

$4.1B +5.1% ▲

5Y CAGR: +8.7%

Profit Margins

Year-over-Year Growth

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$7.8B	$8.1B	$8.5B	$9.3B	$9.5B
YoY Growth	+16.5%	+3.9%	+5.7%	+8.3%	+2.3%
Cost of Revenue	$2.5B	$2.6B	$2.7B	$2.9B	$2.8B
Gross Profit	$5.3B	$5.5B	$5.8B	$6.4B	$6.7B
Gross Margin	68.3%	67.8%	68.3%	69.1%	70.5%
R&D Expenses	$508M	$539M	$614M	$686M	$698M
SG&A Expenses	$2.0B	$2.0B	$2.2B	$2.3B	$2.4B
Operating Expenses	$2.5B	$2.5B	$2.8B	$3.0B	$3.1B
Operating Income	$2.8B	$2.9B	$3.1B	$3.4B	$3.6B
Operating Margin	36.0%	36.2%	35.9%	36.6%	38.0%
Interest Expense	$236M	$237M	$258M	$242M	$243M
Income Before Tax	$2.5B	$2.7B	$2.9B	$3.1B	$3.4B
Tax Expense	$454M	$545M	$596M	$637M	$687M
Net Income	$2.0B	$2.1B	$2.3B	$2.5B	$2.7B
Net Margin	26.2%	26.2%	27.4%	26.9%	28.2%
EPS (Diluted)	$4.27	$4.49	$5.07	$5.47	$6.02
EBITDA	$3.2B	$3.4B	$3.7B	$3.9B	$4.1B
Shares Outstanding	477M	470M	462M	455M	444M

Line Item	FY2024 Q2	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1
Revenue	$2.4B	$2.4B	$2.3B	$2.2B	$2.5B	$2.4B	$2.4B	$2.3B
Cost of Revenue	$703M	$736M	$741M	$654M	$682M	$715M	$743M	$641M
Gross Profit	$1.7B	$1.7B	$1.6B	$1.6B	$1.8B	$1.7B	$1.6B	$1.6B
Gross Margin	70.2%	69.2%	68.0%	70.5%	72.3%	70.2%	68.9%	71.7%
R&D Expenses	$171M	$167M	$186M	$157M	$172M	$170M	$199M	$180M
SG&A Expenses	$581M	$565M	$625M	$563M	$617M	$579M	$619M	$588M
Operating Expenses	$752M	$732M	$811M	$720M	$789M	$749M	$818M	$799M
Operating Income	$906M	$920M	$765M	$846M	$989M	$936M	$826M	$822M
Operating Margin	38.4%	38.5%	33.0%	38.1%	40.2%	39.0%	34.6%	36.3%
Interest Expense	$63M	$61M	$56M	$59M	$58M	$64M	$57M	$62M
Income Before Tax	$780M	$874M	$732M	$810M	$902M	$887M	$761M	$758M
Tax Expense	$156M	$182M	$151M	$179M	$184M	$166M	$158M	$157M
Net Income	$624M	$682M	$581M	$631M	$718M	$721M	$603M	$601M
Net Margin	26.4%	28.6%	25.1%	28.4%	29.2%	30.0%	25.3%	26.6%
EPS (Diluted)	$1.37	$1.50	$1.29	$1.41	$1.61	$1.63	$1.37	$1.42
EBITDA	$970M	$1.1B	$911M	$988M	$1.1B	$1.1B	$947M	$941M
Shares Outstanding	456M	454M	451M	448M	446M	443M	439M	422M

ZTS NYSE